Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195845
Status:
COMPLETED
Last Update Posted:
2017-04-18
First Post:
2005-09-12
Brief Title:
A Double-Blind Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Sponsor:
Cambridge Health Alliance
Organization:
Cambridge Health Alliance
Study Overview
Official Title:
A Phase 4 Double-Blind Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if galantamine augmentaion improves cognition in euthymic bipolar patients In addition the effect of galantamine on clinical measures of functioning and psychopathology will also be assessed
Detailed Description:
The study length is 12 to 24 weeks depending on whether patients enter the crossover Study also involves 3 neuropsychology testings
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GAL-USA-T102 | None | None | None |